Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the akershus cardiac examination 2 study

Clinical Chemistry

Volumn 61, Issue 8, 2015, Pages 1087-1097

  Røsjø, Helge ^a,b   Dahl, Mai Britt ^b   Jørgensen, Marit ^a,b   Røysland, Ragnhild ^a   Brynildsen, Jon ^a   Cataliotti, Alessandro ^a   Christensen, Geir ^a   Høiseth, Arne Didrik ^a   Hagve, Tor Arne ^c   Omland, Torbjørn ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE DISEASE; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DEGLYCOSYLATION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GLYCOSYLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PREVALENCE; PROGNOSIS; SYSTOLIC BLOOD PRESSURE; WHEEZING; AREA UNDER THE CURVE; BLOOD; BLOOD ANALYSIS; CLINICAL TRIAL; COMPLICATION; DEVICES; METABOLISM; MORTALITY; PREDICTIVE VALUE; PROCEDURES;

AGED; AREA UNDER CURVE; BLOOD CHEMICAL ANALYSIS; DYSPNEA; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84938816535     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.239673     Document Type: Article

References (27)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787- 847.
2. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416 -22.
3. MoeGW, Howlett J, Januzzi JL, Zowall H, Canadian Multicenter Improved Management of Patients With Congestive Heart Failure Study I. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007;115: 3103-10.
4. Omland T. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Crit Care Med 2008;36(Suppl):S17-S27.
5. Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, et al. Secretion of glycosylated pro- B-type natriuretic peptide from normal cardiomyocytes. Clin Chem 2011;57:864 -73.
6. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866 -73.
7. Nishikimi T, Okamoto H, Nakamura M, Ogawa N, Horii K, Nagata K, et al. Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure. PloS ONE 2013;8:e53233.
8. Semenov AG, Postnikov AB, TammNN, Seferian KR, Karpova NS, Bloshchitsyna MN, et al. Processing of probrain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem 2009;55:489 -98.
9. Jiang J, Pristera N, Wang W, Zhang X, Wu Q. Effect of sialylated O-glycans in pro-brain natriuretic peptide stability. Clin Chem 2010;56:959 - 66.
10. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselsky MI, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008;54:866 -73.
11. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, Fukuda H, et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 2012;98:152- 61.
12. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37: 379 - 85.
13. Januzzi JL Jr., Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005;95:948 -54.
14. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AHB, Duc P, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly multinational study. J AmColl Cardiol 2003;41:2010 -7.
15. O'Donoghue M, Chen A, Baggish AL, Anwaruddin S, Krauser DG, Tung R, et al. The effects of ejection fraction on N-terminal proBNP and BNP levels in patients with acute CHF: Analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail 2005;11:S9 -S14.
16. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Revised 2011. www.goldcopd.org/uploads/users/files/GOLD-Report-2011-Feb21.pdf (Accessed June 2015).
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31- 41.
18. Kundu S, Aulchenko YS, van Duijn CM, Janssens AC. PredictABEL: An R package for the assessment of risk prediction models. Eur J Epidemiology 2011;26: 261- 4.
19. Demler OV, Pencina MJ, D'Agostino RB Sr. Misuse of DeLong test to compare AUCs for nested models. Stat Med 2012;31:2577- 87.
20. Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ.Onthe C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 2011;30:1105-17.
21. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76:832- 8.
22. Hammerer-Lercher A, Halfinger B, Sarg B, Mair J, Puschendorf B, Griesmacher A, et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008;54:858 - 65.
23. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160 - 6.
24. Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Boukef R, et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J 2014;35: 3434 - 41.
25. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071- 8.
26. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 2005; 294:1944 -56.
27. Røsjø H, Tamm NN, Kravdal G, Seferian KR, Høiseth AD, Nygård S, et al. Diagnostic utility of a single-epitope sandwich B-type natriuretic peptide assay in stable coronary artery disease: data from the Akershus Cardiac Examination (ACE) 1 Study. Clin Biochem 2012;45: 1269 -75.